Much appreciate Oliver Sartor’s editorial comment on our LRRC15-RIT.

Big Cancer Breakthrough UCLA Scientists Develop Antibody That Hunts and Destroys Aggressive Cancers UCLA scientists have developed a powerful new cancer fighting antibody, DUNP19, that can both detect and destroy some of the deadliest, most treatment resistant tumors like

A team of researchers led by @davidulmert has identified a promising new treatment strategy that can detect, kill & reprogram aggressive, treatment-resistant tumors like osteosarcomas & glioblastoma. https://t.co/HVb5RbCFvS

Demonstrating DUNP19, a monoclonal antibody targeting LRRC15, as a highly specific radio-theranostic modality for the non-invasive detection and mitigation of pro-tumorigenic mechanisms & immunotherapy resistance. @UCLA #STTT #OpenAccess: https://t.co/QzubXpC76S

Congratulations to Dr. David Ulmert @davidulmert and team for the promising new LRRC15-targeting radionuclide therapy for aggressive, treatment-resistant tumors!

https://t.co/1jd0TZAt7p

Human kallikrein 2 (encoded by the KLK2 gene; KLK2) is a novel target expressed in prostate cancer cells. KLK2 pipeline — from radiopharmaceuticals to bispecifics and CAR-T —underscores an exciting era where KLK2-based modalities may transform prostate cancer diagnosis and

🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abst5017: Dr #CapucineBaldini presenting #Pasritamig in mCRPC 🔑 KEY TAKE AWAYS - #Pasritamig well tolerated (<10% G1 CRS @ RP2D) with promising antitumor activity. - Proof of concept for #KLK2 as a target amenable to T-cell

🔎Phase 1 results of JNJ-78278343 (pasritamig) in mCRPC? A first in class bispecific T-cell engager targeting human kallikrein2... a specific prostate antigen ✅Remarkable safety profile differentiated from prior T-cell engages with/ low rates of TRAE and infrequent CRS (8.9%,

Excited to share the first results from our ⁦@JNJInnovation⁩ new KLK2xCD3 investigational agent called pasritamig, a first-in-class, Bispecific T-Cell Engager Targeting Human Kallikrein 2 (KLK2) in #mCRPC. #MyCompany

Oral presentation here @ASCO #ASCO25 describing a new target and mechanism in Prostate Cancer. #MyCompany

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from @GustaveRoussy et al. Full abstract → [ https://t.co/2FzVXUaPso] @ASCO @ASCOPost @JCO_ASCO

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac)-labeled antibody targeting human kallikrein 2, for #mCRPC. Presentation by @morr316 @MSKCancerCenter. #ASCO24 written coverage by @zklaassen_md @GACancerCenter > https://t.co/4OvFbTQjzy

There have been calls by some Muslim leaders to boycott Jewish products in solidarity with Palestine! We would like to help the Muslim world in their boycott, and as such, here is a list of things that need to be avoided...

Den talande tystnaden är öronbedövande. Den antisemitism som blottat sig i samhället är skrämmande. Fler behöver träda fram och ställa sig upp och visa sitt stöd för vår judiska minoritet som är under bred attack i Sverige och i omvärlden! Det är oacceptabelt! #NeverAgain

The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer ⁦@CD_AACR⁩ ⁦@SWOG⁩ ⁦@AndrewMWaters⁩

EBRT increased AR pathway activity + [89Zr]11B6 uptake in PC bearing mice + [89Zr]11B6 uptake correlated with #hK2 protein levels. Further evaluation provided, [89Zr]11B6-PET imaging could be a potential monitoring tool for EBRT (or other treatments targeting AR axis/hK2)

[89Zr]11B6-#PET imaging as a potential tool to monitor treatment response in #ProstateCancer: @davidulmert et al. show that #hK2 expression is a proxy of #AndrogenReceptor activity, which can be detected by non-invasive [89Zr]11B6-PET imaging

Exciting news! Our article on utilizing hK2-PET (89Zr-11B6) to assess AR-activity in PCa post external beam irradiation is now published in MCR as the cover story! Big thanks to the editorial team and associate editor @adscheid33 for their support:

Read our April Issue: https://t.co/Ikby2QqDja